Scientific Programme


Scientific committee


Chair: F. Bandello, Italy
Co-Chair: N. Bressler, USA
B. Corcostegui, Spain
Coordinators: B. Falcomatà,Italy
M. Battaglia Parodi, Italy

Friday, 12th October



3D Surgery video session

09.30-13.30 3D COURSE
(M. Romano, Italy)

[NO CME ACTIVITY]


Coordinator: A. Capone (USA), B. Corcostegui (Spain)

[NO CME ACTIVITY]

14.30-15.00 Ocular trauma in the hands of vitreoretinal surgeon
(R. Rejdak, Poland; A. Junemann, Germany)
15.00-15.30 Innovation in vitreoretinal surgery, including 3D displays and heads up imaging
(S. Rizzo, Italy)
15.30-16.00 Update in giant retinal break surgery
(B. Corcostegui, Spain)
16.00-16.30 Macular hole and vitreoretinal interface surgery
(including intraoperative OCTA)
(A. Capone, USA)
16.30- 17.00 3D surgery: How far can we go
(K.Kayat, France)
17.00-17.30 Why the 3D in retinal surgery?
(F. Devin, France)

17.30-18.00 Discussion and closing remarks


Saturday, 13th October


Opening ceremony


08.30 – 09.00 F. Bandello, Italy
B. Corcóstegui, Spain
G. Guarnaccia, Switzerland
R. Redjak, Poland
M. Rekas, Poland
Welcome from Professor Miroslaw Wielgos, MD, PhD.

Rector, Medical University of Warsaw,
Head of the 1st Department of Obstetrics and Gynecology – Warsaw, Poland


SESSION 1: Diabetic Retinopathy


Chairs: N. Bressler, USA
A. Loewenstein, Israel

09.00-09.10 Real-world evidence of anti-VEGF effects on DME
(S. Sivaprasad, UK)
09.10-09.20 Persistent DME beyond 6 anti-VEGF injections
(S. Bressler, USA)
09.20-09.30 Dexamethasone: When first line and when second line therapy?
(A. Loewenstein, Israel)
09.30-09.45 Fluocinolone Acetonide: Current indications and Outcomes
(J. Cunha-Vaz, Portugal)

09.45-10.05 Case Study from the speakers:
1. Pseudophakic eye with center-involved DME and visual acuity 20/50 or worse
(S. Sivaprasad, UK)
2. PDR with center-involved DME
(S. Bressler, USA)
3. Center-involved DME with blurry vision but very good visual acuity (20/20)
(A. Loewenstein, Israel)
4. Acute vitreous hemorrhage with no prior PRP and no TRD on ultrasound
(J. Cunha- Vaz, Portugal)

10.10-10.55 MASTER CLASSES

  1. industry-sponsored symposium
  2. industry-sponsored symposium
  3. industry-sponsored symposium
  4. industry-sponsored symposium
  5. industry- sponsored symposium

SESSION 2: AMD


Chairs: F. Bandello, Italy
F. Behar- Cohen, Switzerland

11.00-11.10 PRN vs. Treat and Extend Regimen with different Anti-VEGF molecules
(M. Larsen, Denmark)
11.10-11.20 Role of brolucizumab in Neovascular AMD
(M. Zarbin, USA)
11.20-11.30 New treatment perspective in AMD
(A. Pollack, Israel)
11.30-11.40 When to Switch to Other Anti-VEGF Drugs?
(F. Behar- Cohen, Switzerland)




ESASO GRADUATION


Chairs: B. Corcostegui (Spain) – G. Guarnaccia (Switzerland)

[NO CME ACTIVITY]

11.45-12.15 Winner Posters Presentation, Winner Young Ophthalmologists,Esaso Graduation and Presentation of the Fellowship



LECTIO MAGISTRALIS


12.15-12.30 Lectio Magistralis – Global Burden of Diseases Projects
(R. Bourne, UK)



SESSION 3: RETINAMOUR


Chairs: S. Bressler(USA), M. Rekas (Poland)

[NO CME ACTIVITY]

12.30-13.00 Clinical cases debated between speaker and moderator

12.30  

 

 

CS01 CHOROIDAL NEOVASCULARIZATION SECONDARY TO CHOROIDAL NEVUS

Vaiva Stankeviciute (1), Andrius Cimbalas (2), Rimvydas S. Asoklis (2)

Vilnius University Hospital Santaros Klinikos, Centre of Eye Diseases, Vilnius       (LITHUANIA),(2) Vilnius University, Faculty of Medicine, Vilnius (LITHUANIA)

12.37  

 

 

CS02 MYOPIC CHOROIDAL NEOVASCULARIZATION – A DIAGNOSTIC CHALLENGE AND USEFULNESS OF OCT-ANGIOGRAPHY

Nuno Moura-Coelho(1), Marco Dutra-Medeiros (1), Miguel Vieira (1), Catarina Xavier (1), Manuel Deslandes Noronha (1), Ana Luisa Basilio (1), Rita Flores (1)

(1)    Centro Hospitalar Lisboa Central (CHLC), LISBON (PORTUGAL)

12.44  

 

CS03 SELF-RESOLVING HUGE SEROUS MACULAR DETACHMENT WITH JUVENILE NORMAL TENSION OAG IN A FEMALE PATIENT

Ahmed Alkaliby (1), Mohammed Elbradey (1)

(1) Tanta University Eye Hospital, Tanta (EGYPT)

12.51  

 

 

CS04 HIDDING BEHIND PRESBYOPIA

Mariana Oliveira, Joana Providência, João Pedro Marques (1,2), Rufino Silva (1,2)

(1) Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra, Coimbra (PORTUGAL), (2) Faculty of Medicine, University of Coimbra, Coimbra (PORTUGAL)



LUNCH


13.00-14.00 LUNCH


SESSION 4: IMAGING


Chairs: A. Pollack (Israel),  M. Goldstein (Israel)

14.00-14.10 Wide-field angiography
(M. Goldstein, Israel)
14.10-14.20 Wide-field retinal photography
(F. Bandello, Italy)
14.20-14.30 Indications to OCT-A
(A. Koh, Singapore)
14.30-14.40 Wide-field OCT
(A. Pollack, Israel)

14.40-15.00 Cases Study from the speakers

15.05-15.25 COFFEE BREAK

15.25-16.10 MASTER CLASS

  1. industry-sponsored symposium
  2. industry-sponsored symposium
  3. industry-sponsored symposium
  4. industry-sponsored symposium

SESSION 5: MANAGEMENT OF DIABETIC RETINOPATHY AND AMD: THE POLISH CONTRIBUTION TO THE STANDARD OF CARE


Chairs: R. Rejdak, M. Zarbin

16.10 16.18 Current treatment of neovascular AMD in Poland
(S. Teper, Poland)
16.18-16.26 Practical use of anti VEGF agents and steroids in therapy of DME
(J. Kaluzny, Poland)
16.26-16.34 Surgical treatment of severe complications of DR
(R. Rejdak, Poland)
16.34-16.42 New data on combination therapy for DME
(J. Mackiewicz, Poland)
16.42-16.50 Surgical treatment of advanced ROP
(M. Stopa, Poland)
16.50-17.00 Comments and closing remarks by Chairs



17.00-17.15 Closure of the meeting and farewell

Submit your clinical case >>

Participants are encouraged to submit medical and surgical case studies. Case studies can be submitted from 19 February 2018 until 16 July 2018.
The Scientific Committee will review and select up to four of the submitted cases for presentation.
Selected submissions will be notified by 27 August 2018.

Accepted cases will be presented by the authors and discussed during the*Retinamour Clinical Case session with an international expert panel.
*Retinamour: Study Cases Discussion
(1 case in 10 minutes -5 minutes presentation (max 4 slides) + 5 minutes discussion)
• A call is launched for the presentation of unusual or representative clinical cases on retinal or macular disease.
• The scientific committee will make a selection of max 4 cases among the cases presented.
• The selected speaker(one of the attendants whose clinical case was choosed) will present it
• the chairs will rapidly comment the case with the speaker during the presentation and at the end of it the audience may pose questions.
Eligible case studies should, but are not restricted to, focus on:
• Interesting diagnosis and/or treatment
• Controversial management
• Interesting follow-up period